Start Your Search
MS 17 - Lessons Learned from Negative Trials (ID 539)
- Event: WCLC 2017
- Type: Mini Symposium
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 1
- Moderators:V. Sriuranpong, Johan F. Vansteenkiste
- Coordinates: 10/17/2017, 15:45 - 17:30, Room 303 + 304
MS 17.06 - Avoiding Phase II-III Attrition: Enhanced Biomarkers, Better Drugs or Improved Trial Design? (ID 7726)
15:45 - 17:30 | Presenting Author(s): John Crowley
In this talk I will cover reasons why phase III trials are "negative" and what can be done to increase the rate of true positive results. Reasons for failure in phase III include inactive agents, poor statistical design, and inadequate implementation. With targeted agents including immunotherapy, additional issues of statistical design arise, as well as assay reliability. I will review the trials discussed in this section (PROCLAIM, MAGRIT, METLung, CheckMate026) with a view towards assessing the reasons these trials might have been negative, and make some suggestions for future trials.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.